5 Key Takeaways

• 1

  Four major medical organizations have issued guidelines for clinicians prescribing GLP-1 receptor agonists for obesity treatment.

• 2

  The guidelines address issues such as medication adherence, side effects, and long-term efficacy of GLP-1 therapy.

• 3

  Patients on GLP-1s may experience significant weight loss but face challenges like gastrointestinal side effects and nutritional deficiencies.

• 4

  The advisory recommends comprehensive assessments and monitoring of lean mass and bone health for patients starting GLP-1 therapy.

• 5

  Cost-effectiveness analyses indicate that GLP-1s do not meet accepted thresholds for cost-effective therapy despite their effectiveness.